KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBITDA (2019 - 2025)

Aurinia Pharmaceuticals' EBITDA history spans 7 years, with the latest figure at $210.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 17975.75% year-over-year to $210.9 million; the TTM value through Dec 2025 reached $287.2 million, up 4822.88%, while the annual FY2025 figure was $287.2 million, 4822.88% up from the prior year.
  • EBITDA reached $210.9 million in Q4 2025 per AUPH's latest filing, up from $31.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $210.9 million in Q4 2025 to a low of -$50.4 million in Q1 2021.
  • Average EBITDA over 5 years is -$3.7 million, with a median of -$12.4 million recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 94.25% in 2021, then skyrocketed 17975.75% in 2025.
  • A 5-year view of EBITDA shows it stood at -$33.4 million in 2021, then increased by 23.37% to -$25.6 million in 2022, then decreased by 4.21% to -$26.7 million in 2023, then skyrocketed by 104.38% to $1.2 million in 2024, then surged by 17975.75% to $210.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EBITDA are $210.9 million (Q4 2025), $31.7 million (Q3 2025), and $21.4 million (Q2 2025).